We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Teva and Eisai to Co-Develop Drug for Alzheimer's

By Biotechdaily staff writers
Posted on 29 May 2003
A long-term strategic alliance for the development of rasagiline for Alzheimer's and other diseases has been announced by Teva Pharmaceutical Industries Ltd. More...
(Jerusalem, Israel) and Eisai Co., Ltd. (Tokyo, Japan). The two companies will also co-promote the drug for Parkinson's disease following approval by the US Food and Drug Administration (FDA).

Rasagiline, developed by Teva and the Technion Research and Development Foundation (Haifa, Israel), is a selective and potent irreversible monoamine oxidase type B (MAO-B) inhibitor agent. Phase III clinical trials involving more than 1,500 patients with Parkinson's disease who took the compound showed statistically significant results.

"We are very pleased to partner with Eisai, a world leader in the field of Alzheimer's,” said Israel Makov, president and CEO of Teva. "This agreement is consistent with our strategy to align ourselves with partners, sharing with them the challenges and the opportunities of our innovative pipeline.”

Teva develops, manufactures, and markets generic and innovative human pharmaceuticals. The company's research and development are focused on developing novel drugs for diseases of the central nervous system. Eisai is a research-based healthcare company that discovers, develops, and markets products in more than 30 countries.





Related Links:
Teva
Eisai

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.